PDS Biotechnology Corporation (PDSB)

Triple Therapy Registration Trial Requirements Announced


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
February 28, 2023
Report ID: 25641
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


PDS Biotechnology Corporation
PDS Biotechnology Corporation
Healthcare
Biotechnology
Ticker
PDSB
Current Price
$6.66 0.45%
Market Cap
$192.4M
Price Target
Refer to Report
Volume
378.2K
52wk Range
$2.89 - $13.65
Related Research Reports
3/2/2023

Peer-Reviewed Journal Published PDS0301 Studies
Peer-Reviewed Journal Published PDS0301 Studies (PDSB)
2/28/2023

Triple Therapy Registration Trial Requirements Announced
Triple Therapy Registration Trial Requirements Announced (PDSB)
1/4/2023

PDS Licenses Merck’s IL-12 Used In Its Combination Studies
PDS Licenses Merck’s IL-12 Used In Its Combination Studies (PDSB)
12/29/2022

Triple Therapy Data Shows Large Improvements Over Standard of Care
Triple Therapy Data Shows Large Improvements Over Standard of Care (PDSB)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2023 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.